Action Durect - DRRX

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,8059

Prix Achat

0,7712

Prix Vente

0,83

Volume échangé

47 388

0,77 Fourchette du Jour 0,815

0,701 Plage de 52 semaines 1,88

Cap du marché

25,017M

Clôture Veille

0,769

Ouverture

0,775

Dernière Transaction

0.7712

Dernière heure de transaction

Volume financier

US$ 37 108

VWAP

0,783066

Volume moyen (3 m)

101 091

Actions en circulation

31 041 981

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,88

Bénéfice par action (BPA)

-0,89

Chiffre d'affairess

8,55M

Bénéfice net

-27,62M

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeli... Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.durect.com

Siège social

Wilmington, Delaware, USA

Fondé

Durect Corp est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker DRRX. Le dernier cours de clôture d'Durect était de US$0,77. Au cours de la dernière année, les actions de Durect ont été négociées dans une fourchette de prix de US$ 0,701 à US$ 1,88.

Durect compte actuellement 31 041 981 actions en circulation. La capitalisation boursière d'Durect est de US$23,87 million. Durect a un ratio cours/bénéfice (ratio PE) de -0.88.

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.0648	8.74375927675	0.7411	0.788899	0.7295	61588	0.75299964	CS
4	-0.0541	-6.29069767442	0.86	0.87	0.71	56106	0.78719483	CS
12	-0.1273	-13.6412344621	0.9332	1.022	0.701	101091	0.83185815	CS
26	-0.3141	-28.0446428571	1.12	1.655	0.701	82321	1.04562734	CS
52	-0.2041	-20.2079207921	1.01	1.88	0.701	112076	1.16503843	CS
156	-5.8941	-87.971641791	6.7	9.70001	0.4703	339267	3.74898009	CS
260	-19.2941	-95.9905472637	20.1	29.6	0.4703	623179	14.46129768	CS

DRRX - Frequently Asked Questions (FAQ)

What is the current Durect share price?

The current share price of Durect is US$ 0,8059

How many Durect shares are in issue?

Durect has 31 041 981 shares in issue

What is the market cap of Durect?

The market capitalisation of Durect is USD 23,87M

What is the 1 year trading range for Durect share price?

Durect has traded in the range of US$ 0,701 to US$ 1,88 during the past year

What is the PE ratio of Durect?

The price to earnings ratio of Durect is -0,88

What is the cash to sales ratio of Durect?

The cash to sales ratio of Durect is 2,83

What is the reporting currency for Durect?

Durect reports financial results in USD

What is the latest annual turnover for Durect?

The latest annual turnover of Durect is USD 8,55M

What is the latest annual profit for Durect?

The latest annual profit of Durect is USD -27,62M

What is the registered address of Durect?

The registered address for Durect is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Durect website address?

The website address for Durect is www.durect.com

Which industry sector does Durect operate in?

Durect operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 10,1006 (148,78%)	149,38M
EDITEditas Medicine Inc	US$ 3,19 (83,33%)	49,89M
SINTSiNtx Technologies Inc	US$ 4,79 (69,86%)	70,97M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
AGHAureus Greenway Holdings Inc	US$ 3,8501 (42,07%)	1,02M
CNSPCNS Pharmaceuticals Inc	US$ 0,0838 (-41,19%)	88,17M
HCTIHealthcare Triangle Inc	US$ 0,4409 (-38,76%)	3,19M
NKLANikola Corporation	US$ 0,4711 (-38,49%)	110,5M
BPTHBio Path Holdings Inc	US$ 0,1322 (-37,05%)	2,14M
GLSTUGlobal Star Acquisition Inc	US$ 7,26 (-36,04%)	4,41k
ADTXAditxt Inc	US$ 0,1288 (17,09%)	612,1M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0616 (13,03%)	482,51M
SMCISuper Micro Computer Inc	US$ 60,25 (7,97%)	338,03M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
NVDANVIDIA Corporation	US$ 139,23 (-0,12%)	168,02M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Durect Corp (DRRX) Cours

Durect Corp (DRRX)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Durect Corp

DRRX Dernières nouvelles

Form 8-K - Current report

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Form 8-K - Current report

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

Form 8-K - Current report

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Form 8-K - Current report

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

DRRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités